[go: up one dir, main page]

ME03016B - Derivat piridina - Google Patents

Derivat piridina

Info

Publication number
ME03016B
ME03016B MEP-2018-91A MEP201891A ME03016B ME 03016 B ME03016 B ME 03016B ME P201891 A MEP201891 A ME P201891A ME 03016 B ME03016 B ME 03016B
Authority
ME
Montenegro
Prior art keywords
pyridine derivative
relates
useful
urat1
lesh
Prior art date
Application number
MEP-2018-91A
Other languages
German (de)
English (en)
French (fr)
Inventor
Akinobu Maruyama
Hirofumi Kamada
Mika Fujinuma
Susumu Takeuchi
Hiroshi Saitoh
Yoshimasa Takahashi
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of ME03016B publication Critical patent/ME03016B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

Apstrakt Predmetni pronalazak odnosi se na derivat piridina koji je koristan kao farmaceutsko sredstvo. Konkretnije, odnosi se na derivat piridina koji ima inhibitornu aktivnost prema URAT1 i koji je koristan u tretmanu ili prevenciji bolesti koje se dovode u vezu sa URAT1, kao što su giht, hiperurikemija, hipertenzija, bubrežne bolesti kao što je intersticijalni nefritis, dijabetes, arteroskleroza, ili Leš-Nihanov sindrom, kao i na prekursor leka, farmaceutski prihvatljivu so ili solvat  takvog jedinjenja .   1
MEP-2018-91A 2012-11-14 2013-11-13 Derivat piridina ME03016B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012250661 2012-11-14
EP13854714.6A EP2944633B1 (en) 2012-11-14 2013-11-13 Pyridine derivative
PCT/JP2013/080706 WO2014077285A1 (ja) 2012-11-14 2013-11-13 ピリジン誘導体

Publications (1)

Publication Number Publication Date
ME03016B true ME03016B (me) 2018-10-20

Family

ID=50731196

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2018-91A ME03016B (me) 2012-11-14 2013-11-13 Derivat piridina

Country Status (36)

Country Link
US (2) US9637469B2 (me)
EP (2) EP2944633B1 (me)
JP (2) JP5774238B2 (me)
KR (1) KR20150082194A (me)
CN (2) CN104797570B (me)
AR (1) AR093468A1 (me)
AU (2) AU2013345894B2 (me)
BR (1) BR112015010977A2 (me)
CA (1) CA2891408A1 (me)
CL (1) CL2015001279A1 (me)
CY (1) CY1120127T1 (me)
DK (1) DK2944633T3 (me)
ES (1) ES2662444T3 (me)
HR (1) HRP20180451T1 (me)
HU (1) HUE037736T2 (me)
IL (2) IL238539A (me)
LT (1) LT2944633T (me)
MA (1) MA38078B1 (me)
ME (1) ME03016B (me)
MX (1) MX2015003672A (me)
NO (1) NO2944633T3 (me)
NZ (1) NZ708031A (me)
PE (1) PE20150974A1 (me)
PH (1) PH12015501037A1 (me)
PL (1) PL2944633T3 (me)
PT (1) PT2944633T (me)
RS (1) RS57090B1 (me)
RU (1) RU2640588C2 (me)
SA (1) SA515360431B1 (me)
SG (2) SG11201503770VA (me)
SI (1) SI2944633T1 (me)
SM (1) SMT201800322T1 (me)
TW (1) TWI666205B (me)
UA (1) UA117359C2 (me)
WO (1) WO2014077285A1 (me)
ZA (1) ZA201503322B (me)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3144306B1 (en) * 2014-05-13 2017-11-15 Teijin Pharma Limited Pyrazine derivative
MX2016014692A (es) * 2014-05-13 2017-02-23 Teijin Pharma Ltd Polimorfos cristalinos novedosos de derivados de piridina y metodo para producirlos.
MX2018011214A (es) * 2016-03-15 2019-03-28 Bayer Cropscience Ag Sulfonamidas sustituidas para controlar plagas animales.
CN107286156A (zh) * 2016-04-05 2017-10-24 江苏新元素医药科技有限公司 新型urat1抑制剂及其在医药上的应用
CN106008488B (zh) * 2016-05-20 2018-10-30 广东东阳光药业有限公司 氰基吲哚类衍生物及其制备方法和用途
ES2961901T3 (es) * 2016-05-23 2024-03-14 Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd Tiofeno, método de fabricación del mismo y aplicación farmacéutica del mismo
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas
CN110312718B (zh) 2017-01-10 2023-02-28 拜耳公司 作为害虫防治剂的杂环烯衍生物
CN108658879A (zh) * 2017-03-29 2018-10-16 天津药物研究院有限公司 一种urat1抑制剂及其制备方法和用途
CN109251184B (zh) * 2017-07-13 2021-06-15 浙江海正药业股份有限公司 一种2-三氟甲基苯磺酰胺类衍生物的医药用途
CA3093445A1 (en) 2018-03-08 2019-11-28 Incyte Corporation Aminopyrazine diol compounds as pi3k-.gamma. inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
TWI820231B (zh) 2018-10-11 2023-11-01 德商拜耳廠股份有限公司 用於製備經取代咪唑衍生物之方法
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2021089673A1 (de) 2019-11-07 2021-05-14 Bayer Aktiengesellschaft Substituierte sulfonylamide zur bekämpfung tierischer schädlinge
JP2023532548A (ja) 2020-07-02 2023-07-28 バイエル・アクチエンゲゼルシヤフト 有害生物防除剤としてのヘテロサイクレン誘導体
CN114315729B (zh) * 2021-12-09 2024-01-26 大连理工大学 1-苄基-2，4-二芳基咪唑类化合物、合成方法及其在抗肿瘤上的应用
WO2025026738A1 (en) 2023-07-31 2025-02-06 Bayer Aktiengesellschaft 6-[5-(ethylsulfonyl)-1-methyl-1h-imidazol-4-yl]-7-methyl-3-(pentafluoroethyl)-7h-imidazo[4,5-c]pyridazine derivatives as pesticides

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599032A (en) * 1977-03-04 1981-09-30 May & Baker Ltd Imidazole derivatives having herbicidal activity
JPS5671073A (en) 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4770689A (en) 1986-03-10 1988-09-13 Janssen Pharmaceutica N.V. Herbicidal imidazole-5-carboxylic acid derivatives
PL149675B1 (pl) 1986-03-10 1990-03-31 Sposób wytwarzania nowych pochodnych kwasu 1-metyl0-1h-imidaz0l0karb0ksyl0weg0-5
DD260928A5 (de) 1986-06-06 1988-10-12 Ciba-Geigy Ag,Ch Verfahren zur herstellung neuer aralkylimidizolderivate
US4851424A (en) 1986-06-06 1989-07-25 Ciba-Geigy Corporation 1-Phenyl-lower alkyl-imidazole 4- or 5-carboxamide compounds which are useful in the treatment of epilepsy
JPH08119936A (ja) 1994-10-18 1996-05-14 Fujisawa Pharmaceut Co Ltd 複素環式誘導体
IT1295405B1 (it) 1997-09-30 1999-05-12 Merck Sharp & Dohme Italia S P Uso di un antagonista recettoriale di angiotensina ii per la preparazione di farmaci per aumentare il tasso di sopravvivenza di
AU2001275794A1 (en) 2000-07-28 2002-02-13 Sumitomo Pharmaceuticals Co. Ltd. Pyrrole derivatives
JP3999128B2 (ja) 2001-02-22 2007-10-31 帝人株式会社 ベンゾ［ｂ］チオフェン誘導体、およびその製造方法
AU2003902828A0 (en) * 2003-06-05 2003-06-26 Fujisawa Pharmaceutical Co., Ltd. Dpp-iv inhibitor
CA2706858C (en) * 2007-11-27 2013-12-24 Ardea Biosciences, Inc. Imidazole and triazole derivatives and methods of use
WO2009148599A1 (en) * 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
JP2012502049A (ja) * 2008-09-04 2012-01-26 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及びそれを使用する方法。
JP2010202575A (ja) 2009-03-03 2010-09-16 Takeda Chem Ind Ltd 複素環化合物
BR112012000606A2 (pt) * 2009-07-10 2016-11-22 Brigham & Womens Hospital análogos de etomidato que não inibem a síntese de esteróides adrenocorticais
CN102035579B (zh) * 2009-09-28 2014-09-03 夏普株式会社 信息反馈方法和用户设备
AR081930A1 (es) * 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
JP5485811B2 (ja) * 2010-06-23 2014-05-07 株式会社ジャパンディスプレイ 双方向シフトレジスタ、及びこれを用いた画像表示装置
SG187795A1 (en) * 2010-08-11 2013-03-28 Millennium Pharm Inc Heteroaryls and uses thereof

Also Published As

Publication number Publication date
TWI666205B (zh) 2019-07-21
JP2015091865A (ja) 2015-05-14
IL243193A0 (en) 2016-02-29
PL2944633T3 (pl) 2018-08-31
IL238539A (en) 2017-11-30
AR093468A1 (es) 2015-06-10
PH12015501037A1 (en) 2015-07-27
UA117359C2 (uk) 2018-07-25
MA38078B1 (fr) 2017-04-28
JP6293068B2 (ja) 2018-03-14
EP2944633B1 (en) 2018-01-31
JPWO2014077285A1 (ja) 2017-01-05
DK2944633T3 (en) 2018-03-12
RS57090B1 (sr) 2018-06-29
ES2662444T3 (es) 2018-04-06
CN104797570B (zh) 2017-11-07
CN107721931A (zh) 2018-02-23
ZA201503322B (en) 2016-01-27
KR20150082194A (ko) 2015-07-15
LT2944633T (lt) 2018-03-12
CN104797570A (zh) 2015-07-22
EP2944633A4 (en) 2016-01-06
SG11201503770VA (en) 2015-06-29
HRP20180451T1 (hr) 2018-06-01
SI2944633T1 (en) 2018-06-29
PE20150974A1 (es) 2015-07-04
EP3339302A1 (en) 2018-06-27
SMT201800322T1 (it) 2018-07-17
US20150284358A1 (en) 2015-10-08
IL238539A0 (en) 2015-06-30
PT2944633T (pt) 2018-05-09
US20170190694A1 (en) 2017-07-06
SA515360431B1 (ar) 2017-11-15
EP2944633A1 (en) 2015-11-18
RU2015122698A (ru) 2017-01-10
CL2015001279A1 (es) 2015-06-26
HUE037736T2 (hu) 2018-09-28
MX2015003672A (es) 2015-06-15
TW201422603A (zh) 2014-06-16
US9637469B2 (en) 2017-05-02
AU2013345894B2 (en) 2017-05-25
AU2013345894A1 (en) 2015-05-21
NZ708031A (en) 2018-04-27
RU2640588C2 (ru) 2018-01-10
HK1211940A1 (en) 2016-06-03
WO2014077285A1 (ja) 2014-05-22
CA2891408A1 (en) 2014-05-22
AU2013345894A9 (en) 2015-11-12
NO2944633T3 (me) 2018-06-30
CY1120127T1 (el) 2018-12-12
BR112015010977A2 (pt) 2017-07-11
JP5774238B2 (ja) 2015-09-09
AU2017204665A1 (en) 2017-07-27
MA38078A1 (fr) 2016-09-30
SG10201705852PA (en) 2017-08-30

Similar Documents

Publication Publication Date Title
ME03016B (me) Derivat piridina
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
CY1121144T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
HUE053113T2 (hu) Bardoxolon-metil 2,2-difluorpropionamid-származéka, annak gyógyszerkészítményei és polimorfjai bizonyos betegségek kezelésében történõ alkalmazásra
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX2019010446A (es) Compuestos de anillos fusionados biciclicos derivados de piridilo como inhibidores de fgfr4.
CL2013001654A1 (es) Compuestos derivados de 6-amino-2-fenilamino-1h-bencimidazol-5-carboxamida; composicion farmaceutica; y su uso en el tratamiento y/o prevencion de las enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
HUE054389T2 (hu) Eljárás CFTR-mediálta betegségek kezelésére szolgáló gyógyászati kompozíciók elõállítására
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX377845B (es) Inhibidores de calicreína plasmática humana.
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA201892050A1 (ru) Способ получения замещенных 5-фтор-1h-пиразолопиридинов
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
MX2016014939A (es) Derivados de carboxamida.
EA201692298A1 (ru) Производные карбоксамидов
EE201300004A (et) Kombineeritud ravimkoostis sdame-veresoonkonnaga seotud haiguste v?i seisundite raviks
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
JO3192B1 (ar) مركب بنزوثيازولون